For Emergency Care Experts:

• Sudden, severe or unusual headache
• Brief loss of consciousness
• Nausea and/or vomiting
• Focal neurologic deficits
• Development of a painful stiff neck over several hours.^1,2

1. Mayberg MR, Batjer HH, Dacey R et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Hearth Association. Stroke 1994;25:2315-2328.
   
   
2. Findlay JM. Current management of aneurysmal subarachnoid hemorrhage guidelines from the Canadian Neurosurgical Society. Can J Neurol Sci 1997; 24:161-170.
   
   

DO NOT ADMINISTER NIMOTOP INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE-THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMOTOP CAPSULES HAVE BEEN INJECTED PARENTERALLY

(See WARNINGS and DOSAGE AND ADMINISTRATION.)

• In patients with SAH, Nimotop® controls damage with a low side effect profile.
  
  
• Decreased blood pressure is the most common side effect, occurring in 4.4% of patients. Blood pressure should be monitored during therapy.¹
  
  
• Other side effects occurring at a low frequency of ≥1.0% include headache, nausea, and bradycardia.¹
  
  
• No clinically significant effects on hematologic factors, renal or hepatic function, or carbohydrate metabolism have been causally associated with oral nimodipine.¹
  
  
• Nimotop® does not appear to affect anesthetic management.²
  

1. Nimotop® (nimodipine) Capsules Prescribing Information December 2005
   
   
2. Stullken EH, Johnston WE, Prough DS. Implications of nimodipine prophylaxis of cerebral vasospasm on anesthetic management during intracranial aneurysm clipping. J. Neurosurg. 1985; 62:200-205.